EVP Academic & Research Affairs

Lilly Days

Eli Lilly logo

 

Lilly Days in Houston Meeting

UT MD Anderson & UTHealth

 

 

 A G E N D A


 

Thursday, November 21, 2013


** NOTE NEW LOCATION **

The University of Texas Health Science Center at Houston

Denton A. Cooley, MD and Ralph C. Cooley, DDS University Life Center

7440 Cambridge Street, Houston, TX 77054

* REGISTRATION IS NOW CLOSED *

8:30a - 9:00a                     

Check-In and Networking 

PLENARY SESSIONS and ROUNDTABLES
(Open to All)
9:00a - 9:30a

Introduction and Overview - Mike Myers, Senior Director, Global External R&D

  • Eli Lilly and Company Introduction
  • Eli Lilly Areas of Interest
  • Eli Lilly pipeline
  • Eli Lilly Partnerships
9:30a - 9:50a Lilly Public Private Partnerships  - Dale Edgar, Distinguished Research Fellow, Global External R&D
9:50a - 10:20a         Lilly’s Open Innovation Drug Discovery Program2 - Alan Palkowitz, Vice President, Discovery Chemistry and Technologies
10:20a - 10:40a          Lilly Ventures3 - Armen Shanafelt, Lilly Ventures, Venture Partner
10:40a - 11:00a Coffee Break
11:00a - 11:30a

Concurrent Roundtable Session4 #1 – Lily Team Members5 and UT Faculty

  • Diabetes/Cardiovascular Research 
  • Oncology Research
  • Neuroscience
  • Translational Medicine
  • Autoimmune Research
  • Financing
  • Open Innovation Drug Discovery
11:30a - 11:40a Roundtable transition
11:40a - 12:20p

Concurrent Roundtable Session4 #2 – Lilly Team Members5 and UT Faculty

  • Diabetes/Cardiovascular Research 
  • Oncology Research
  • Neuroscience
  • Translational Medicine
  • Autoimmune Research
  • Financing
  • Open Innovation Drug Discovery
12:30p - 1:00p  Lunch
AFTERNOON MEETINGS
(By Invitation Only)
1:00p - 3:30p One-on-one Discussions (30 minutes) - UT Faculty and Lilly Team Members5  (scheduled individually with selected faculty members prior to visit)


 

Lilly’s Open Innovation Drug Discovery Program is a program whereby investigators may submit compounds (without revealing their structures) that Lilly tests for biological activities using their in-house screening assays. Based upon initial results investigators and their institutions and Lilly decide whether to enter further discussions to determine if there is mutual interest in further collaboration and/or data publication.  (See https://openinnovation.lilly.com/dd/docs/oidd_brochure_english.pdf  

Lilly Ventures is the venture capital arm of Eli Lilly and Company responsible for life science investing in North America and Europe. It’s primary goal is to facilitate the success of companies in areas of interest through early to expansion stage investments and value-adding resources. It typically invests in the life science sector including biotechnology, healthcare IT, biopharmaceutical, and medical technology. (See http://www.lillyventures.com/ )

Roundtable sessions will involve an initial overview of Lilly’s specific interests, functions, and strategies in the specified therapeutic area followed by a discussion/ questions on overlapping interests of faculty members at UT institutions.

Lilly Team Attendees

  • Mike Myers- Sr. Director, Global External R&D, Due Diligence
  • Alan Palkowitz- Vice President, Discovery Chemistry and Technologies
  • Dale Edgar- Distinguished Research Fellow, Global External R&D, Public, Private Partnerships
  • Armen Shanafelt- Lilly Ventures, Venture Partner
  • Brian Bloomquist- Sr. Director, Global External R&D, Diabetes Business Unit
  • Gary Borzillo- Advisor, Global External R&D, Oncology Business Unit
  • Steve Wilkie- External Scientist, Global External R&D, Translational Medicine
  • Adam Houghton- Sr. Director, Global External R&D, BioMedicines Business Unit and Translational Medicine
  • Brenda Grimes- Advisor, Global External R&D, Translational Medicine